Skip to main content
Article thumbnail
Location of Repository

Characterization of STAT3 activation and expression in canine and human osteosarcoma

By Stacey L Fossey, Albert T Liao, Jennifer K McCleese, Misty D Bear, Jiayuh Lin, Pui-Kai Li, William C Kisseberth and Cheryl A London
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2666757
Provided by: PubMed Central

Suggested articles

Citations

  1. (2005). A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA
  2. (2006). Abastado JP: Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets
  3. (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res
  4. (2008). Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. Faseb J
  5. (2008). Argyle DJ: Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J
  6. (2008). Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma.
  7. (2006). Comparative gene expression profiling of canine and human osteosarcoma.
  8. (2002). Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood
  9. (2007). Coqueret O: The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med
  10. (2008). Cordero di Montezemolo L: In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep
  11. (1998). Crompton MR: Expression of v-src in mammary epithelial cells induces transcription via STAT3. Biochem J
  12. (1994). Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target
  13. (2007). Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res
  14. (2005). DE: Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res
  15. (2000). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des
  16. (2007). Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study.
  17. (1998). Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung.
  18. (1995). et al.: Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res
  19. (2007). et al.: Identification of a novel pyrazolo[3,4-d] pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.
  20. (2004). et al.: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene
  21. (2005). Frank DA: Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res
  22. (2004). Hanneman WH: Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol
  23. (2003). Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene
  24. (2004). Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med
  25. (2006). JD: STAT3 is activated in a subset of the Ewing sarcoma family of tumours.
  26. (2000). Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene
  27. (2008). Kleinerman ES: Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther
  28. (2005). Liggitt D: Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther
  29. London CA: A novel small molecule Met inhibitor, PF236 exhibits biological activity against canine osteosarcoma.
  30. (2005). London CA: Characterization, expression and function of c-Met in canine spontaneous cancers. Veterinary and Comparative Oncology
  31. (2002). London CA: Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood
  32. (2005). Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol
  33. (2006). MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res
  34. (2007). NJ: Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res
  35. (2001). Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res
  36. (1989). PE: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
  37. (2008). PK: Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg, and Med Chem Lett
  38. (1998). RE: Postirradiation sarcomas in Sprague-Dawley rats. Radiat Res
  39. (2004). Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene
  40. (2000). S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res
  41. (2007). Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.
  42. (2007). Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets
  43. (2002). Smithgall TE: Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain.
  44. (2000). STAT proteins: novel molecular targets for cancer drug discovery. Oncogene
  45. (2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. P r o c N a t l A c a d S c i U S A
  46. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.
  47. (2007). Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res
  48. (2003). Thamm DH, Radinsky R: c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis
  49. (2003). Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood
  50. (2008). Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer
  51. (1993). Woods VL Jr: Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.